Macarena de la Fuente, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Agios Pharmaceuticals, Inc. at 33.4% of the total.
Across 15 payments — averaging $355.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$2K
- Servier Pharmaceuticals LLC$2K
- Telix Pharmaceuticals$1K
- Foundation Medicine, Inc.$250
- Servier Bioinnovation$197
- Janssen Scientific Affairs, LLC$43
Across 595 payments — averaging $8191.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$3.4M
- Merck$940K
- E.r. Squibb & Sons, L.L.C.$243K
- Agios Pharmaceuticals, Inc.$140K
- Servier Pharmaceuticals LLC$84K
- Caris MPI, Inc.$84K
- plus $26K from 2 others
What the payments were for
- Consulting fees$1,78033%
- Speaking & faculty fees$1,72532%
- Travel & lodging$1,05320%
- Food & beverage$78215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 2 | $1,785 |
| Servier Pharmaceuticals LLC | 3 | $1,660 |
| Telix Pharmaceuticals | 6 | $1,406 |
| Foundation Medicine, Inc. | 1 | $250 |
| Servier Bioinnovation | 1 | $197 |
| Janssen Scientific Affairs, LLC | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$1,176
- FOUNDATIONONE LIQUID$250
- FOUNDATIONFOCUS$250
- FOUNDATIONONE CDX$250
- FOUNDATIONONE HEME$250
- FOUNDATIONONE$250
- TIBSOVO$125
How this compares
$5,340 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleostineLomustine | 13 | $9,350 |
| Levetiracetam | 28 | $652 |
| Dexamethasone | 32 | $288 |
| Ondansetron Hcl | 11 | $159 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $57 |
Paid to pharmacies, not to this prescriber.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.